Skip to content

Study · Randomized controlled trial · n = 60 · 2018

7 results

L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.

Ghajar A, Khoaie-Ardakani MR, Shahmoradi Z, Alavi AR, Afarideh M, Shalbafan MR, Ghazizadeh-Hashemi M, Akhondzadeh S

Psychiatry research3 Feb 2018Cited by 27 (Europe PMC)

PMID29427913 (opens in a new tab)DOI10.1016/j.psychres.2018.02.012 (opens in a new tab)PepBankPUB-29427913
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In stable schizophrenia on risperidone, carnosine improved PANSS negative scores more than placebo.

    In plain wordsIn people with stable schizophrenia receiving risperidone, carnosine improved negative symptom scores more than placebo.

    Peptide
    L-carnosine
    Outcome
    DecreasePANSS negative scores
    Study

    n = 60

    Comparator
    placebo on stable risperidone
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    2 gr/day in two divided doses · eight weeksAs given in this study (human).

    Source sentences

    Summary
    L-carnosine resulted in greater improvement of negative scores as well as total PANSS scores but not positive subscale scores compared to placebo.
    4 context sentences
    Summary · context
    Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted.
    Summary · context
    Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study.
    Summary · context
    The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks.
    Summary · context
    Sixty patients completed the trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In stable schizophrenia on risperidone, carnosine improved total PANSS scores more than placebo.

    In plain wordsIn people with stable schizophrenia receiving risperidone, carnosine improved total symptom scores more than placebo.

    Peptide
    L-carnosine
    Outcome
    DecreasePANSS total scores
    Study

    n = 60

    Comparator
    placebo on stable risperidone
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    2 gr/day in two divided doses · eight weeksAs given in this study (human).

    Source sentences

    Summary
    L-carnosine resulted in greater improvement of negative scores as well as total PANSS scores but not positive subscale scores compared to placebo.
    4 context sentences
    Summary · context
    Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted.
    Summary · context
    Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study.
    Summary · context
    The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks.
    Summary · context
    Sixty patients completed the trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In stable schizophrenia on risperidone, carnosine did not improve PANSS positive scores more than placebo.

    In plain wordsIn people with stable schizophrenia receiving risperidone, carnosine did not improve positive symptom scores more than placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changePANSS positive scores
    Study

    n = 60

    Comparator
    placebo on stable risperidone
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    2 gr/day in two divided doses · eight weeksAs given in this study (human).

    Source sentences

    Summary
    L-carnosine resulted in greater improvement of negative scores as well as total PANSS scores but not positive subscale scores compared to placebo.
    4 context sentences
    Summary · context
    Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted.
    Summary · context
    Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study.
    Summary · context
    The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks.
    Summary · context
    Sixty patients completed the trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In stable schizophrenia on risperidone, HDRS scores and changes did not differ between carnosine and placebo.

    In plain wordsIn people with stable schizophrenia receiving risperidone, depression scores and changes did not differ between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeHDRS scores and changes
    Study

    n = 60

    Comparator
    placebo on stable risperidone
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2 gr/day in two divided doses · eight weeksAs given in this study (human).

    Source sentences

    Summary
    HDRS scores and its changes did not differ between the two groups.
    4 context sentences
    Summary · context
    Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted.
    Summary · context
    Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study.
    Summary · context
    The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks.
    Summary · context
    Sixty patients completed the trial.
  5. 05HumanRandomized controlled trialSafety outcome

    In stable schizophrenia on risperidone, ESRS scores remained constant in both carnosine and placebo groups.

    In plain wordsIn people with stable schizophrenia receiving risperidone, movement symptom scores remained constant in both carnosine and placebo groups.

    Peptide
    L-carnosine
    Outcome
    No significant changeESRS scores
    Study

    n = 60

    Comparator
    baseline in both groups
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    2 gr/day in two divided doses · eight weeksAs given in this study (human).

    Source sentences

    Summary
    Both groups demonstrated a constant ESRS score during the trial course.
    4 context sentences
    Summary · context
    Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted.
    Summary · context
    Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study.
    Summary · context
    The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks.
    Summary · context
    Sixty patients completed the trial.
  6. 06HumanRandomized controlled trialSafety outcome

    In stable schizophrenia on risperidone, other side effect frequency did not differ significantly between carnosine and placebo.

    In plain wordsIn people with stable schizophrenia receiving risperidone, other side effects did not differ significantly between carnosine and placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeOther side effects
    Study

    n = 60

    Comparator
    placebo on stable risperidone
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 gr/day in two divided doses · eight weeksAs given in this study (human).

    Source sentences

    Summary
    Frequency of other side effects was not significantly different between the two groups.
    4 context sentences
    Summary · context
    Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted.
    Summary · context
    Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study.
    Summary · context
    The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks.
    Summary · context
    Sixty patients completed the trial.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In stable schizophrenia on risperidone, assignment to add-on carnosine versus placebo significantly predicted changes in primary negative symptoms in an adjusted regression model.

    In plain wordsWith risperidone, assignment to carnosine versus placebo predicted negative symptom changes in stable schizophrenia, after adjustment for other symptoms and variables.

    Peptide
    L-carnosine
    Outcome
    Direction not reportedAdjusted primary negative symptom changes
    Study

    n = 60

    Comparator
    placebo on stable risperidone
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    2 gr/day in two divided doses · eight weeksAs given in this study (human).

    Source sentences

    Summary
    In a multiple regression analysis model (controlled for positive, general psychopathology, depressive and extrapyramidal symptoms, as well as other variables), the treatment group significantly predicted changes in primary negative symptoms.
    4 context sentences
    Summary · context
    Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted.
    Summary · context
    Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study.
    Summary · context
    The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks.
    Summary · context
    Sixty patients completed the trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.